Prime Medicine (NYSE:PRME) Upgraded at

Prime Medicine (NYSE:PRMEGet Rating) was upgraded by to a “sell” rating in a research note issued on Tuesday.

Prime Medicine Price Performance

Shares of NYSE:PRME opened at $14.27 on Tuesday. Prime Medicine has a 12-month low of $11.07 and a 12-month high of $21.73.

See Also

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with's FREE daily email newsletter.